Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,826 across all filing types
Latest filing 2021-04-05 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司独立董事关于公司对外担保情况的专项说明及独立意见
Audit Report / Information Classification · 90% confidence The document is a special statement and independent opinion by independent directors regarding the company's external guarantees, referencing regulatory notices from the China Securities Regulatory Commission and the company's articles of association. It discusses compliance with regulations and the status of external guarantees during the reporting period. The document is short (565 characters) and does not contain detailed financial data or audit results itself, but rather an attestation or opinion related to regulatory compliance and guarantees. This fits the category of an Audit Report / Information (AR) as it relates to audit findings and regulatory compliance on a specific issue, rather than a full annual report or a simple announcement. Therefore, the classification is AR with high confidence. FY 2020
2021-04-05 Chinese
哈药集团股份有限公司2020年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Directors' Report" for the year 2020 by Harbin Pharmaceutical Group Co., Ltd. It details the activities, attendance, and opinions of the independent directors during the year, including their oversight on management appointments, related party transactions, auditor reappointment, internal controls, and information disclosure. The document is a narrative report on governance and director duties rather than a financial report or announcement. It does not contain financial statements or earnings data, nor is it a brief announcement or a proxy solicitation. It fits best under Board/Management Information (MANG) as it relates to board members' roles and activities, specifically independent directors' annual report on their duties and oversight.
2021-04-05 Chinese
哈药集团股份有限公司关于续聘会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of an accounting firm (Beijing Xinghua Certified Public Accountants) for auditing services for the year 2021. It details the qualifications, experience, and independence of the accounting firm, the audit fees, and the approval process by the board and independent directors. There is no actual audit report or financial statements included, only a notice about the appointment of the auditor. The document length is relatively short (3036 characters) and it serves as a formal announcement rather than a full audit report or annual report. Therefore, it fits best under the category of Audit Report / Information (AR) as it relates to audit matters but is not a full annual report or financial statement filing. FY 2020
2021-04-05 Chinese
哈药集团股份有限公司独立董事关于会计政策变更的独立意见
Audit Report / Information Classification · 90% confidence The document is a statement from independent directors regarding a change in accounting policies. It references compliance with accounting standards and regulatory bodies but does not contain financial statements or detailed financial data. The document is short (390 characters) and serves as an independent opinion on a specific governance matter rather than a full audit report or annual report. It is not a certification letter but an independent opinion on accounting policy changes, which aligns with governance or audit-related information. Given the nature and length, it fits best under Audit Report / Information (AR) as it relates to accounting policy changes and independent director opinions on such matters. FY 2020
2021-04-05 Chinese
哈药集团股份有限公司独立董事对公司续聘会计师事务所的事前认可声明
Audit Report / Information Classification · 95% confidence The document is a statement from independent directors regarding the pre-approval of the company's proposal to renew the appointment of an accounting firm for audit work. It references the 2020 audit work summary report and the proposal to renew the auditor. The document is short (594 characters) and does not contain actual financial statements or detailed audit results, but rather an opinion and approval related to the audit engagement. This fits the category of Audit Report / Information (AR), which includes standalone audit reports and related approvals, excluding full annual reports. Therefore, the document is best classified as AR. FY 2020
2021-04-05 Chinese
哈药集团股份有限公司独立董事关于计提资产减值准备的独立意见
Audit Report / Information Classification · 90% confidence The document is a statement of independent directors' opinion regarding the provision for asset impairment for the year 2020. It references compliance with accounting standards and company policies, and it is an independent opinion rather than a full audit report or annual report. The document is very short (411 characters) and does not contain detailed financial data or comprehensive audit results. It is a standalone opinion related to accounting treatment, which aligns with the category of Audit Report / Information (AR). FY 2020
2021-04-05 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.